[A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia].
We report a case of good response to chemo-endocrine therapy with slight alopecia. A 55-year-old woman was diagnosed as advanced breast cancer with T4c, N3, M1, Stage IV, who was left cervical node-positive. She received 4 cycles of CTF (cyclophosphamide 100 mg/body/day 1-14, THP 30 mg/body/days 1,8, and 5-FU 750 mg/body/days 1, 8 4 wq) therapy in addition to oral tamoxifen (20 mg/body) administration. After this treatment, the primary tumor was markedly reduced (PR), and only slight alopecia was observed. Generally, 3 cycles of CAF (CEF) therapy induced severe alopecia (grade 3). But this CTF regimen caused grade 1 alopecia. Most women have strong resistance to alopecia. It seems that the quality of life for breast cancer patients was affected by the extent of the alopecia. Therefore, CTF therapy should be considered effective for advanced breast cancer patients while reducing the extent of alopecia.
Terazaki
Yasuhiro
Y
Dept. of Surgery, Ohmuta National Hospital.
Nagamatsu
Hironori
H
Ono
Hironori
H
Iwakuma
Nobutaka
N
Shirouzu
Kazuo
K
D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000556:secondary; D000505:Alopecia / Q000139:chemically induced*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011788:Quality of Life; D013629:Tamoxifen / Q000008:administration & dosage
D013629:Tamoxifen; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D005472:Fluorouracil